A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved ...
Researchers at Oregon Health & Science University have identified a type of enzyme with a complicated name. Cell migration ...
UC San Diego scientists discover enzyme responsible for scrambling cancer genomes; results could enable new treatments for ...
Patent Protects Novel Application of Gedeptin Therapy Across Multiple Solid Tumor Types; Supports Expansion of Gedeptin ...
Phase 1/2 Trial Confirms Safety With Repeated Dosing Supporting Further Development in Early-stage Disease and Combination Treatment Settings ATLANTA, GA - December 8, 2025 (NEWMEDIAWIRE) - GeoVax ...
Mycosis fungoides, the most prevalent CTCL subtype, accounts for the majority of cases. Although early-stage disease has a five-year survival rate of roughly 88%, it is a chronic cancer with ...
As big pharmas including Takeda and Novo Nordisk flee the cell therapy space and smaller biotechs shutter their operations, ...
An international study led by scientists at Flinders University and at South China University of Technology has uncovered a new vulnerability in prostate cancer cells that could help improve treatment ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological ...
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) Breakthrough Therapy ...
LOS ANGELES, CALIFORNIA - JULY 24: Dr. Eric Esrailian speaks onstage during the 2025 Social Impact Summit by The Hollywood Reporter and Social Impact Fund on July 24, 2025 at the DGA in Los Angeles, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback